AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2808940 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 60
Study 1154272 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin group (n = 7)
Number of subjects: 16
Study 1154272 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte group (n = 9)
Number of subjects: 16
Study 1154272 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin group
Number of subjects: 16
Study 1154272 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte group
Number of subjects: 16
Study 31255586 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 50
Study 31255586 — intervention group
Group type: COMPARATOR
Intervention: Education/support condition
Number of subjects: 50
Study 29225313 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee polyphenols (CPPs) 297.8 mg daily for 4 weeks
Number of subjects: 0
Study 29225313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29225313 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee polyphenols (CPPs)
Number of subjects: 0
Study 29225313 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee polyphenols (CPPs) in low RR subgroup
Number of subjects: 0
Study 26514447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 60
Study 26514447 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 60
Study 23116208 — intervention group
Group type: EXPERIMENTAL
Intervention: linaclotide (290 μg) for 12 weeks (Trial 31)
Number of subjects: 1608
Study 23116208 — intervention group
Group type: EXPERIMENTAL
Intervention: linaclotide (290 μg) for 26 weeks (Trial 302)
Number of subjects: 1608
Study 21864392 — intervention group
Group type: EXPERIMENTAL
Intervention: si-ni-tang (2.25 grams 4 times a day for 7 days or till shock reversal)
Number of subjects: 0
Study 21864392 — intervention group
Group type: COMPARATOR
Intervention: placebo (2.25 grams 4 times a day for 7 days or till shock reversal)
Number of subjects: 0
Study 19339127 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy Isoflavones Extract (SIE) 120mg daily
Number of subjects: 84
Study 19339127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 17302023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pillar(R) Palatal Implant System
Number of subjects: 0
Study 17302023 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15039249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-season dance training for 12 weeks (n = 16)
Number of subjects: 26
Study 15039249 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 26
Study 11376828 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous patch electrode
Number of subjects: 30
Study 11376828 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous array electrode
Number of subjects: 30
Study 9692286 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing by practice nurses
Number of subjects: 0
Study 7823270 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthrinse (positive control)
Number of subjects: 15
Study 7823270 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental CPC/essential oil mouthrinse
Number of subjects: 15
Study 7823270 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer prebrushing mouthrinse
Number of subjects: 15
Study 7823270 — intervention group
Group type: COMPARATOR
Intervention: Negative control rinses (two types)
Number of subjects: 15
Study 3167526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam hydrochloride (20 mg)
Number of subjects: 49
Study 3167526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 28981312 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical assault and sexual victimization by intimate partners
Number of subjects: 179
Study 28981312 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD symptoms
Number of subjects: 179
Study 27894271 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise program involving progressive and challenging balance training and neuromuscular and functional training of the lower limbs, conducted at home by physiotherapists, once a week for the first three months, and twice a week at home thereafter, totaling 18 sessions.
Number of subjects: 82
Study 27894271 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 82
Study 25063725 — intervention group
Group type: EXPERIMENTAL
Intervention: iNO (10 ppm)
Number of subjects: 124
Study 25063725 — intervention group
Group type: COMPARATOR
Intervention: Placebo gas (controls)
Number of subjects: 124
Study 22462558 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/losartan 5 mg/100 mg combination
Number of subjects: 142
Study 22462558 — intervention group
Group type: COMPARATOR
Intervention: Losartan 100 mg
Number of subjects: 142
Study 20569455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement containing polyunsaturated fatty acids and Humulus lupulus extract (active group)
Number of subjects: 0
Study 20569455 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo group)
Number of subjects: 0
Study 20569455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement (active group)
Number of subjects: 0
Study 18501669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac transplant patients
Number of subjects: 38
Study 18501669 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 38
Study 15928240 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (60% carbohydrate, 25% fat)
Number of subjects: 13
Study 15928240 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (30% carbohydrate, 55% fat)
Number of subjects: 13
Study 12762083 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based smoking cessation intervention
Number of subjects: 59
Study 10512920 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol
Number of subjects: 2253
Study 10512920 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 2253
Study 8624233 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisdom Straight toothbrush
Number of subjects: 0
Study 8624233 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisdom Plaque Control toothbrush
Number of subjects: 0
Study 8624233 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisdom Angled toothbrush
Number of subjects: 0
Study 8624233 — intervention group
Group type: COMPARATOR
Intervention: Oral-B 35 toothbrush
Number of subjects: 0
Study 1828549 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct insertion of reusable conventional laparoscopic trocar
Number of subjects: 200
Study 1828549 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct insertion of disposable shielded trocar
Number of subjects: 200
Study 1828549 — intervention group
Group type: COMPARATOR
Intervention: Previous pneumoperitoneum by Veress needle insertion
Number of subjects: 200
Study 6991353 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 236
Study 6991353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 31912674 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion hysterectomy after CCRT
Number of subjects: 175
Study 31912674 — intervention group
Group type: COMPARATOR
Intervention: Surveillance after CCRT
Number of subjects: 175
Study 29616587 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade fixation with a cannulated headless compression screw
Number of subjects: 22
Study 29616587 — intervention group
Group type: COMPARATOR
Intervention: Retrograde fixation with a cannulated headless compression screw
Number of subjects: 22
Study 28025309 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) using the Prevena NPWT device
Number of subjects: 64
Study 28025309 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 64
Study 27515752 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle suprapubic cutaneous stimulation using cold saline-soaked gauze in circular motions
Number of subjects: 354
Study 27515752 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (control)
Number of subjects: 354
Study 27515752 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle suprapubic cutaneous stimulation using cold saline-soaked gauze
Number of subjects: 354
Study 24928948 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber ICDs
Number of subjects: 100
Study 24928948 — intervention group
Group type: COMPARATOR
Intervention: Single-chamber ICDs
Number of subjects: 100
Study 22732468 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic vaccine
Number of subjects: 0
Study 22732468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22732468 — intervention group
Group type: EXPERIMENTAL
Intervention: ATI week 16
Number of subjects: 0
Study 19810667 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative reflective assignment in a community psychosocial program for 4 weeks
Number of subjects: 73
Study 19810667 — intervention group
Group type: COMPARATOR
Intervention: Conventional 14-week clinical experience
Number of subjects: 73
Study 18474463 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS065D
Number of subjects: 40
Study 18474463 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 40
Study 16192542 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 cm distal to the greater trochanter (group proximal)
Number of subjects: 50
Study 16192542 — intervention group
Group type: COMPARATOR
Intervention: 30 cm distal to the greater trochanter (group distal)
Number of subjects: 50
Study 12894612 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (4 weeks treatment)
Number of subjects: 27
Study 12894612 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 weeks treatment)
Number of subjects: 27
Study 10227808 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled interleukin-5 (IL-5)
Number of subjects: 8
Study 8916983 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-back hormone replacement therapy (HRT) with cyclical oestradiol/norgestrol in combination with Zoladex (goserelin acetate)
Number of subjects: 51
Study 8916983 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oestrogen/progestogen given for 21 months after initial GnRH agonist treatment for 3 months
Number of subjects: 51
Study 8916983 — intervention group
Group type: COMPARATOR
Intervention: Progestogen only
Number of subjects: 51
Study 8445225 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon, 6 million units, intramuscularly, once per week for 24 weeks
Number of subjects: 36
Study 8445225 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 36
Study 8445225 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon
Number of subjects: 36
Study 3953351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lorcainide (LOR) 2 mg/kg then 200 mg/24hr
Number of subjects: 30
Study 3953351 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (LID) 1 mg/kg then 2 mg/min
Number of subjects: 30
Study 30045770 — intervention group
Group type: EXPERIMENTAL
Intervention: Rock and Water intervention (Light condition: core team of teachers trained)
Number of subjects: 720
Study 30045770 — intervention group
Group type: EXPERIMENTAL
Intervention: Rock and Water intervention (Standard condition: core team of teachers and whole school team trained)
Number of subjects: 720
Study 30045770 — intervention group
Group type: EXPERIMENTAL
Intervention: Rock and Water intervention (Plus condition: core team of teachers, whole school team trained, and parents involved)
Number of subjects: 720
Study 30045770 — intervention group
Group type: COMPARATOR
Intervention: Control condition (Care As Usual)
Number of subjects: 720
Study 27716692 — intervention group
Group type: EXPERIMENTAL
Intervention: Marked introducer needle
Number of subjects: 62
Study 27716692 — intervention group
Group type: COMPARATOR
Intervention: Unmarked introducer needle
Number of subjects: 62
Study 27716692 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 24643636 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (180 mg eicosapentaenoic acid and 120 mg docosahexaenoic acid), three times daily for 4 months
Number of subjects: 54
Study 24643636 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 54
Study 24643636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 25119571 — intervention group
Group type: EXPERIMENTAL
Intervention: Uzara (80 mg/8 hours for two doses, then 40 mg/8 hours)
Number of subjects: 60
Study 25119571 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (400 mg/6 hours)
Number of subjects: 60
Study 25119571 — intervention group
Group type: EXPERIMENTAL
Intervention: Uzara
Number of subjects: 60
Study 25119571 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 60
Study 23091132 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine added to drinking water during preslaughter feed withdrawal
Number of subjects: 40
Study 23091132 — intervention group
Group type: COMPARATOR
Intervention: Preslaughter feed withdrawal without chlorine
Number of subjects: 40
Study 19428086 — intervention group
Group type: EXPERIMENTAL
Intervention: LIA + SCB
Number of subjects: 323
Study 19428086 — intervention group
Group type: COMPARATOR
Intervention: LIA
Number of subjects: 323
Study 19428086 — intervention group
Group type: COMPARATOR
Intervention: No-needle jet anesthesia
Number of subjects: 323
Study 17486470 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progesterone therapy (EPT)
Number of subjects: 60
Study 17486470 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 60
Study 17486470 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 15847356 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride hydrochloride 50mg three times daily for two weeks
Number of subjects: 56
Study 15847356 — intervention group
Group type: COMPARATOR
Intervention: Domperidone 10mg three times daily for two weeks
Number of subjects: 56
Study 12200521 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 ng recombinant human TNF alpha
Number of subjects: 10
Study 12200521 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 10
Study 9806037 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (300 micrograms/day up to 10 days)
Number of subjects: 0
Study 9806037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9097710 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNA index (percentage of PCNA positive nuclei)
Number of subjects: 103
Study 9097710 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNA index as a new parameter in malignancy index (MI)
Number of subjects: 103
Study 1909525 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety condition (presence of senior and junior experimenters, junior presented as professional, personal contact with senior)
Number of subjects: 18
Study 1909525 — intervention group
Group type: COMPARATOR
Intervention: Non-safety condition (senior experimenter left on bogus emergency, junior presented as 'student', subjects alone)
Number of subjects: 18
Study 1909525 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety scores (pre-inhalation)
Number of subjects: 18
Study 1909525 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety scores (median-split analysis)
Number of subjects: 18
Study 6623361 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified amino acid solution rich in branched chains and low in aromatic amino acids and methionine (F080)
Number of subjects: 22
Study 6623361 — intervention group
Group type: COMPARATOR
Intervention: Neomycin
Number of subjects: 22
Study 31418598 — intervention group
Group type: EXPERIMENTAL
Intervention: C-SSRRMT capsules
Number of subjects: 0
Study 31418598 — intervention group
Group type: COMPARATOR
Intervention: Immediate release market tablets
Number of subjects: 0
Study 28335893 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal LAD stenting
Number of subjects: 8709
Study 28335893 — intervention group
Group type: COMPARATOR
Intervention: Stenting outside proximal LAD
Number of subjects: 8709
Study 27993163 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to transition services (integrated practice unit with multidisciplinary care, dedicated paramedicine providers, and virtual visits)
Number of subjects: 1520
Study 27993163 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1520
Study 24439596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad lib feeding
Number of subjects: 150
Study 24439596 — intervention group
Group type: COMPARATOR
Intervention: Protocol feeding
Number of subjects: 150
Study 22422274 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care with toothbrushing and 0.12% chlorhexidine digluconate
Number of subjects: 436
Study 22422274 — intervention group
Group type: COMPARATOR
Intervention: Oral care without toothbrushing and 0.12% chlorhexidine digluconate
Number of subjects: 436
Study 18635695 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion XR (150 mg/day, increased to 300 mg/day if inadequate response)
Number of subjects: 0
Study 18635695 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine XR (75 mg/day, increased to 150 mg/day if inadequate response)
Number of subjects: 0
Study 18635695 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 17617284 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical epinastine hydrochloride ophthalmic solution 0.05% twice daily for 4 days
Number of subjects: 18
Study 17617284 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic loratadine 10 mg once daily for 4 days
Number of subjects: 18
Study 15089837 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal sacrospinous fixation (SSF)
Number of subjects: 21
Study 15089837 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior intravaginal slingplasty (PIVS)
Number of subjects: 21
Study 15089837 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrocolpopexy (SCP)
Number of subjects: 21
Study 17061489 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole 500 mg twice daily for 7 days
Number of subjects: 45
Study 17061489 — intervention group
Group type: COMPARATOR
Intervention: Oral ampicillin 2 g for 10 days
Number of subjects: 45
Study 9836168 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with chronic unilateral low back pain
Number of subjects: 30
Study 9836168 — intervention group
Group type: COMPARATOR
Intervention: Pain-free controls
Number of subjects: 30
Study 8081076 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenzepine 1.5 mg nocte
Number of subjects: 0
Study 8081076 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenzepine 3 mg nocte
Number of subjects: 0
Study 8081076 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenzepine 5 mg nocte
Number of subjects: 0
Study 8081076 — intervention group
Group type: COMPARATOR
Intervention: Placebo nocte
Number of subjects: 0
Study 1810018 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 0
Study 6285503 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide (n = 20)
Number of subjects: 35
Study 6285503 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (n = 15)
Number of subjects: 35
Study 30730862 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) plus lidocaine
Number of subjects: 84
Study 30730862 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus lidocaine
Number of subjects: 84
Study 28871893 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study 28871893 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein (PRO)
Number of subjects: 12
Study 28871893 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO)
Number of subjects: 12
Study 26979261 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 100
Study 26979261 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 100
Study 23896791 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min Apgar score of 0-3
Number of subjects: 174
Study 23896791 — intervention group
Group type: COMPARATOR
Intervention: 10 min Apgar score >3
Number of subjects: 174
Study 23896791 — intervention group
Group type: EXPERIMENTAL
Intervention: Each point increase in 10 min Apgar scores
Number of subjects: 174
Study 23896791 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min Apgar score of 0
Number of subjects: 174
Study 23896791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled infants with Apgar scores of 0-3
Number of subjects: 174
Study 20111879 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dental treatment
Number of subjects: 380
Study 20111879 — intervention group
Group type: COMPARATOR
Intervention: No invasive treatment
Number of subjects: 380
Study 20111879 — intervention group
Group type: EXPERIMENTAL
Intervention: Other treatment strategies
Number of subjects: 380
Study 19490308 — intervention group
Group type: EXPERIMENTAL
Intervention: Learn Young, Learn Fair program
Number of subjects: 1467
Study 17499284 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily
Number of subjects: 4568
Study 17499284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4568
Study 15196105 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway pressure release ventilation (APRV)
Number of subjects: 58
Study 15196105 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent ventilation (SIMV)
Number of subjects: 58
Study 12174003 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine administered into the ventrogluteal area
Number of subjects: 200
Study 12174003 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine administered into the anterolateral thigh
Number of subjects: 200
Study 9844307 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration perception test, electric current sensitivity test, thermal perception test
Number of subjects: 53
Study 9844307 — intervention group
Group type: COMPARATOR
Intervention: Vibration perception test
Number of subjects: 53